JAMS decides biotech IP dispute
A JAMS arbitrator has reportedly rejected a California biotech company’s claim that one of its co-founders misappropriated trade secrets relating to developing treatments for neurodegenerative diseases.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.